FDA approves Regeneron’s Livsayis for generalised myasthenia gravis
Administered subcutaneously four times annually, the therapy is a small interfering RNA designed to decrease circulating complement component factor 5 protein levels and curb terminal complement activation. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.